Interstitial lung diseases

M Wijsenbeek, A Suzuki, TM Maher - The Lancet, 2022 - thelancet.com
Over 200 interstitial lung diseases, from ultra rare to relatively common, are recognised.
Most interstitial lung diseases are characterised by inflammation or fibrosis within the …

Treatment of fibrotic interstitial lung disease: current approaches and future directions

KA Johannson, N Chaudhuri, A Adegunsoye… - The Lancet, 2021 - thelancet.com
Fibrotic interstitial lung disease (ILD) represents a large group of pulmonary disorders that
are often progressive and associated with high morbidity and early mortality. Important …

Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase …

JM Naccache, S Jouneau, M Didier, R Borie… - The Lancet …, 2022 - thelancet.com
Background The use of cyclophosphamide in patients with acute exacerbation of idiopathic
pulmonary fibrosis (IPF) is unknown. Our study was designed to evaluate the efficacy and …

Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study

RJ Allen, JM Oldham, DA Jenkins… - The Lancet …, 2023 - thelancet.com
Background Idiopathic pulmonary fibrosis (IPF) is an incurable lung disease characterised
by progressive scarring leading to alveolar stiffness, reduced lung capacity, and impeded …

Therapeutic targeting of the respiratory microbiome

SH Chotirmall, D Bogaert, JD Chalmers… - American journal of …, 2022 - atsjournals.org
Culture-independent microbiology has transformed our understanding of the respiratory
microbiome in health and disease (1). Enabled by advances in next-generation sequencing …

The microbiome: an integral player in immune homeostasis and inflammation in the respiratory tract

O Perdijk, R Azzoni, BJ Marsland - Physiological Reviews, 2024 - journals.physiology.org
The last decade of microbiome research has highlighted its fundamental role in systemic
immune and metabolic homeostasis. The microbiome plays a prominent role during …

Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a …

G Raghu, M Ghazipura, TR Fleming… - American journal of …, 2024 - atsjournals.org
Background: Idiopathic pulmonary fibrosis (IPF) carries significant mortality and
unpredictable progression, with limited therapeutic options. Designing trials with patient …

Interstitial Lung Disease: A Review

TM Maher - JAMA, 2024 - jamanetwork.com
Importance Interstitial lung disease (ILD) consists of a group of pulmonary disorders
characterized by inflammation and/or fibrosis of the lung parenchyma associated with …

Targeting growth factor and cytokine pathways to treat idiopathic pulmonary fibrosis

H Ma, S Liu, S Li, Y **a - Frontiers in Pharmacology, 2022 - frontiersin.org
Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease of unknown origin
that usually results in death from secondary respiratory failure within 2–5 years of diagnosis …

Lung microbiome in idiopathic pulmonary fibrosis and other interstitial lung diseases

F Amati, A Stainer, M Mantero, A Gramegna… - International journal of …, 2022 - mdpi.com
Interstitial lung diseases represent a heterogeneous and wide group of diseases in which
factors leading to disease initiation and progression are not fully understood. Recent …